Chris Ryan

Chris Ryan joined OncLive in November 2021 as a senior editor and became the website's managing editor in October 2023. Before arriving at MJH Life Sciences, he spent nearly a decade covering professional and high school sports—including the New Jersey Devils and the NHL from 2016 to 2021—for The Star-Ledger and NJ.com. Email: chryan@onclive.com

Articles

Infinatamab Deruxtecan Shows Encouraging CNS Activity in Extensive-Stage Small Cell Lung Cancer

October 19th 2025

I-DXd showed intracranial efficacy and manageable safety in ES-SCLC with brain metastases, per data from the IDeate-Lung01 study.

Neoadjuvant T-DXd Plus THP Yields pCR Benefit in High-Risk, HER2+ Early-Stage Breast Cancer

October 18th 2025

Neoadjuvant T-DXd followed by THP improved pathological complete response rate in high-risk, HER2-positive early-stage breast cancer.

Incidence of Second Primary Tumors Is Similar Between Adjuvant Cemiplimab and Placebo in High-Risk CSCC

October 18th 2025

Adjuvant cemiplimab and placebo were associated with similar rates of second primary tumors in high-risk CSCC.

Dr Chi on Potential Prognostic Markers for Lutetium Lu 177 Vipivotide Tetraxetan in PSMA+ mCRPC

October 18th 2025

Kim Nguyen Chi, MD, FRCPC, discusses correlative analyses of prognostic subgroups in the phase 2 PR21 study in PSMA-positive mCRPC.

Fruquintinib Plus Sintilimab Improves PFS in Advanced RCC After First-Line VEGFR TKI Therapy

October 18th 2025

Fruquintinib plus sintilimab significantly extended progression-free survival in advanced RCC following first-line VEGFR TKI therapy.

Long-Term MANEUVER Trial Data Spotlight Durable Responses With Pimicotinib in TGCT

October 17th 2025

Long-term data demonstrated durable responses with pimicotinib in tenosynovial giant cell tumor.

Osimertinib Plus Chemo Demonstrates OS Benefit in EGFR+ NSCLC With Poor Prognostic Factors

October 17th 2025

Osimertinib plus chemotherapy improved OS vs osimertinib alone in EGFR-mutated advanced non–small lung cancer, irrespective of poor prognostic factors.

Osimertinib Plus Local Consolidative Therapy Significantly Extends PFS in EGFR-Mutant NSCLC

October 17th 2025

NorthStar findings support osimertinib plus local consolidative therapy in EGFR-mutant non–small cell lung cancer.

Asciminib Receives Positive CHMP Opinion for Ph+ CP-CML

October 17th 2025

The EMA’s CHMP has recommended the approval of asciminib for Philadelphia chromosome–positive chronic myeloid leukemia in chronic phase.

Unmet Needs to Address in Advanced NSCLC

October 16th 2025

Julia Rotow, MD, and Jyoti Malhotra, MD, MPH, discuss unmet needs in advanced NSCLC.

Novel Biomarkers to Watch in Advanced NSCLC

October 16th 2025

Julia Rotow, MD, and Jyoti Malhotra, MD, MPH, discuss novel biomarkers under investigation in advanced NSCLC.

Dr Mahvash on the Clinical Impact of the FDA Approval of SIR-Spheres Y-90 Resin Microspheres for Unresectable HCC

October 16th 2025

Armeen Mahvash, MD, discusses the clinical impact of the FDA approval of SIR-Spheres Y-90 resin microspheres for unresectable hepatocellular carcinoma.

Dr Patel on the FDA Approval of Adjuvant Cemiplimab for High-Risk Cutaneous Squamous Cell Carcinoma

October 16th 2025

Vishal A. Patel, MD, discusses the FDA approval of adjuvant cemiplimab for CSCC at high risk of recurrence following surgery and radiation.

Dr O’Shaughnessy on Highly Anticipated Breast Cancer Data to Watch at ESMO 2025

October 16th 2025

Joyce A. O’Shaughnessy, MD, highlights the breast cancer data being presented at ESMO 2025 that have the greatest potential to shape clinical practice.

Teclistamab Plus Daratumumab Boosts Survival in R/R Myeloma

October 16th 2025

Teclistamab plus daratumumab improved progression-free and overall survival in relapsed/refractory multiple myeloma after 1 to 3 lines of therapy.

Pembrolizumab Plus Chemo With or Without Bevacizumab Improves OS in Platinum-Resistant Ovarian Cancer

October 16th 2025

Pembrolizumab plus chemotherapy with or without bevacizumab improved overall survival in platinum-resistant ovarian cancer.

Dr Perol on Unmet Need for Post Immunotherapy Strategies in Lung Cancer

October 16th 2025

Maurice Perol, MD, discusses the persistent unmet need for effective treatments following progression on immunotherapy in NSCLC.

Dr Peters on the Importance of Consensus Meetings to Address Clinical Ambiguity in Lung Cancer

October 16th 2025

Solange Peters, MD, PhD, discusses the necessity of global consensus meetings to navigate clinical "gray zones" in lung cancer management.

Study Shows ChatGPT Struggles With Patient-Specific Queries, Novel Therapies in Hematologic Malignancies

October 16th 2025

A study found ChatGPT 3.5 was more likely to give incomplete or inaccurate answers to specific hematologic malignancy queries vs general questions.

Toripalimab Plus CCRT Generates 100% ORR, But Safety Concerns Warrant Additional Research in Locally Advanced Cervical Cancer

October 16th 2025

Toripalimab plus CCRT produced a 100% ORR in locally advanced cervical cancer, although the regimen was associated with radiation-related AEs and irAEs.